OCRF & Ovarian Cancer National Alliance are now one strong, united, inspiring voice!
Ovarian Cancer Research Fund (OCRF) and the Ovarian Cancer National Alliance (OCNA) have led the way in advocacy, research and support for patients and their families for over 22 years. As of January 2016, we are pleased to announce we are joining together to form Ovarian Cancer Research Fund Alliance (OCRFA), the largest global organization dedicated to advancing ovarian cancer research while supporting women and their families. Read the exciting news!


Depression and Anxiety Drug May Ease Neuropathy from Chemo

Research published today in the Journal of the American Medical Association showed that the depression and anxiety drug duloxetine effectively treated painful chemotherapy-induced peripheral neuropathy.

Chemotherapy-induced peripheral neuropathy occurs in roughly 20% to 40% of patients treated with chemotherapy agents such as taxanes, platinums, and vinca alkaloids.  The condition can persist for years following treatment and can interfere with quality of life.

Results from the phase III, randomized, double-blinded, placebo-controlled trial shows that over 5 weeks of treatment, patients receiving duloxetine experienced significantly larger mean decreases in pain than patients on placebo.

Click here for more information, and click here to read the scientific abstract.